Selective Serotonin Reuptake Inhibitor (SSRI) updated on 07-01-2025

Neonatal tachypnea

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13112
R49962
Marks - Sertraline (Controls exposed to Bupropion), 2021 Transient tachypnea of the newborn during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.23 [0.84;1.80] C 172/1,653   35/406 207 1,653
ref
S10062
R36573
Bracero, 2016 Tachypnea days before delivery retrospective cohort unexposed, sick Adjustment: No Monotherapy: no or not specified 1.63 [0.08;34.23] C 0/6   4/85 4 6
ref
S5430
R21352
Norby, 2016 Transient tachypnea/other respiratory disease during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 1.70 [1.60;1.90] 819/17,736   15,860/718,533 16,679 17,736
ref
S5423
R19475
Levinson-Castiel, 2006 Tachypnea 3rd trimester retrospective cohort unexposed, disease free Adjustment: No Matched Monotherapy: no or not specified 31.32 [1.81;542.66] C 12/60   0/60 12 60
ref
Total 4 studies 1.59 [1.06;2.37] 16,902 19,455
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Marks - Sertraline (Controls exposed to Bupropion), 2021Marks - Sertraline, 2021 1 1.23[0.84; 1.80]2071,65339%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Bracero, 2016Bracero, 2016 1.63[0.08; 34.23]462%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Norby, 2016Norby, 2016 1.70[1.60; 1.90]16,67917,73658%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Levinson-Castiel, 2006Levinson-Castiel, 2006 31.32[1.81; 542.66]12602%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 55% 1.59[1.06; 2.37]16,90219,4550.5100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls exposed to Bupropion;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.59[1.06; 2.37]16,90219,45555%NAMarks - Sertraline (Controls exposed to Bupropion), 2021 Bracero, 2016 Norby, 2016 Levinson-Castiel, 2006 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 5.07[0.32; 80.59]16,69117,79675%NANorby, 2016 Levinson-Castiel, 2006 2 unexposed, sickunexposed, sick 1.63[0.08; 34.23]46 -NABracero, 2016 1 exposed to other treatment, sickexposed to other treatment, sick 1.23[0.84; 1.80]2071,653 -NAMarks - Sertraline (Controls exposed to Bupropion), 2021 1 Tags Adjustment   - No  - No 2.86[0.44; 18.58]2231,71959%NAMarks - Sertraline (Controls exposed to Bupropion), 2021 Bracero, 2016 Levinson-Castiel, 2006 3   - Yes  - Yes 1.70[1.56; 1.85]16,67917,736 -NANorby, 2016 1 MatchedMatched 31.32[1.81; 542.66]1260 -NALevinson-Castiel, 2006 1 Monotherapy   - no or not specified  - no or not specified 3.10[0.62; 15.61]16,69517,80250%NABracero, 2016 Norby, 2016 Levinson-Castiel, 2006 3   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.23[0.84; 1.80]2071,653 -NAMarks - Sertraline (Controls exposed to Bupropion), 2021 1 All studiesAll studies 1.59[1.06; 2.37]16,90219,45555%NAMarks - Sertraline (Controls exposed to Bupropion), 2021 Bracero, 2016 Norby, 2016 Levinson-Castiel, 2006 40.5100.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.14.11.8650.000Marks - Sertraline (Controls exposed to Bupropion), 2021Bracero, 2016Norby, 2016Levinson-Castiel, 2006

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 5.07[0.32; 80.59]16,69117,79675%NANorby, 2016 Levinson-Castiel, 2006 2 unexposed, sick controlsunexposed, sick controls 1.63[0.08; 34.23]46 -NABracero, 2016 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.23[0.84; 1.80]2071,653 -NAMarks - Sertraline (Controls exposed to Bupropion), 2021 10.510.01.0